Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica, Inc. develops calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The clinical-stage biopharmaceutical company’s lead product candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor based on zegocractin and is being studied across severe inflammatory conditions involving tissue cell injury.
Company news commonly covers financial results, clinical and preclinical updates, regulatory discussions, publications, and corporate developments. Recurring program topics include Auxora data in acute pancreatitis with systemic inflammatory response syndrome, severe COVID-19 pneumonia, and acute kidney injury, as well as preclinical work on CM5480 in pulmonary arterial hypertension.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CalciMedica announced the closing of its merger with Graybug Vision, effective March 20, 2023, which allows its common stock to begin trading on the Nasdaq under the ticker CALC starting March 21, 2023. The merger gives CalciMedica approximately $34 million in cash reserves, anticipated to support operations through mid-2024. Key clinical milestones include Phase 2b results for its lead product, Auxora™, targeting acute pancreatitis, expected in Q4 2023. Additionally, a Research and Development Event will be held on April 27, 2023, to discuss Auxora’s potential in treating life-threatening inflammatory diseases.